AI Agents: The Scientists' New Allies

By Joel Ottosson and Justyna Lisowska, PhD, Genedata

This content is brought to you by Genedata, a Danaher Operating Company.

Biopharma R&D is moving into a new phase shaped by intelligent AI agents that can reason, interact with data systems, and support complex scientific decisions. Their potential is enormous—from uncovering disease biology to shaping trial designs in real time—but readiness across the industry varies widely. Many organizations face challenges rooted in fragmented digital ecosystems, inconsistent data quality, and the need for stronger governance and explainability, especially in GxP settings. To truly benefit from AI agents, companies must build the right data foundation: interoperable systems, high‑quality structured data, and validated environments that ensure traceability and compliance. With these elements in place, AI agents can reliably collaborate with scientific teams and accelerate the path from discovery to development.

Explore their promise, the barriers limiting adoption, and the strategic choices organizations face as they move from early experimentation to scaled, responsible deployment.